ClinicalTrials.gg
RecruitingNCT07736638Updated Aug 3, 2026

A Study to Assess the Safety, Tolerability and How Single Ascending Doses of ABBV-859 Moves Through the Body of Healthy Adult Participants

A Phase 1 interventional study of ABBV-859 and Placebo for ABBV-859 in Healthy Volunteer, sponsored by AbbVie. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-03.

Sponsored by AbbVie · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of this study is to assess the pharmacokinetic (PK), immunogenicity, safety, and tolerability of ABBV-859 after single ascending doses in healthy adult volunteers.

02

Conditions studied

  • Healthy Volunteer

Keywords

  • Healthy Volunteer
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 135 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must voluntarily sign and date an , approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to the initiation of any screening or study-specific procedures.
  • (BMI) is >= 18.0 to \<= 32 kg/m2 after rounding to the tenths decimal at screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead (ECG).

Exclusion criteria

Exclusion Criteria:

  • History of epilepsy, any cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, hematologic, endocrine, immunological, pulmonary, metabolic, neurological or psychiatric disease or disorder, or any uncontrolled medical illness.
  • History of any clinically significant sensitivity or allergy to any medication or food.
  • History of or active medical condition(s) or surgical procedure(s) that might affect gastrointestinal motility, pH, or absorption [e.g., Crohn's disease, celiac disease, gastroparesis, short bowel syndrome, gastric surgery (except pyloromyotomy for pyloric stenosis during infancy), cholecystectomy, vagotomy, bowel resection, etc.].
  • Evidence of dysplasia or history of (including lymphoma and leukemia) other than successfully treated non- cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix.
  • History or evidence of active Tuberculosis disease or latent Tuberculosis infection.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Group 1

    Participants will receive either ABBV-859 single Dose A, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

  • Experimental
    Group 2

    Participants will receive either ABBV-859 single Dose B, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

  • Experimental
    Group 3

    Participants will receive either ABBV-859 single Dose C, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

  • Experimental
    Group 4

    Participants will receive either ABBV-859 single Dose D, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

  • Experimental
    Group 5

    Participants will receive either ABBV-859 single Dose E, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

  • Experimental
    Group 6

    Participants will receive either ABBV-859 single Dose F, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

  • Experimental
    Group 7

    Participants will receive either ABBV-859 single Dose G, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

  • Experimental
    Group 8

    Participants will receive either ABBV-859 single Dose H, or the Placebo equivalent, on Study Day 1

    Drug: ABBV-859 · Drug: Placebo for ABBV-859

Interventions

  • DrugABBV-859

    Oral Tablet

  • DrugPlacebo for ABBV-859

    Oral Tablet

  • DrugABBV-859

    Intravenous (IV) Infusion

  • DrugPlacebo for ABBV-859

    Intravenous (IV) Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not the event is considered causally related to the use of the product.

    Time frame: Up to 99 Days

  2. Maximum Observed Serum Concentration (Cmax) of ABBV-859

    Cmax of ABBV-859

    Time frame: Up to 99 Days

  3. Time to Cmax (Tmax) of ABBV-859

    Time to Cmax (Tmax) of ABBV-859

    Time frame: Up to 99 Days

  4. Terminal Phase Elimination Rate Constant (Beta) of ABBV-859

    Beta of ABBV-859

    Time frame: Up to 99 Days

  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-859

    t1/2 of ABBV-859

    Time frame: Up to 99 Days

  6. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-859

    AUCt of ABBV-859

    Time frame: Up to 99 Days

  7. AUC From Time 0 to the Time Infinity (AUCinf) of ABBV-859

    AUCinf of ABBV-859

    Time frame: Up to 99 Days

  8. Apparent Clearance (CL/F) ABBV-859

    CL/F of ABBV-859

    Time frame: Up to 99 Days

  9. Antidrug Antibody (ADA)

    Incidence and concentration of anti-drug antibodies.

    Time frame: Up to 99 Days

07

Study locations

2 of 2 sites recruiting
  • CenExel ACT- Anaheim Clinical Trials /ID# 284382
    Anaheim, California 92801, United States
    Recruiting
  • Acpru /Id# 284029
    Grayslake, Illinois 60030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Feb 2027, 7 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 27, 2026
First posted
Jul 30, 2026
StartActual
Jul 28, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Aug 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07736638
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jul 30, 2026
Start date
Jul 28, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Aug 3, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion